CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...